找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Immunotherapy of Melanoma; Anand Rotte,Madhuri Bhandaru Book 2016 Springer International Publishing AG 2016 Melanoma.Immunotherapy.Check p

[复制链接]
楼主: 欺骗某人
发表于 2025-3-30 09:26:28 | 显示全部楼层
Mechanisms of Immune Evasion by Cancerlls that are harmful for host’s survival. Immunosurveillance, is a process by which immune system monitors the cells/tissues continuously and eliminates the modified or transformed cells. While the immune cells have unique abilities to detect the abnormally dividing cells, tumors also develop specia
发表于 2025-3-30 14:43:07 | 显示全部楼层
Interferon-α2bde inhibition of viral replication, activation of immune cells, and up regulation of antigen presentation by stimulating MHC antigen expression in the target cells. IFN-α is a Type I interferon which signals through IFNAR receptor complex that consists of IFNAR1 and IFNAR2; it mainly has antiprolife
发表于 2025-3-30 17:37:11 | 显示全部楼层
Interleukin-2e discovered. It mainly functions as a T-cell growth factor. Its discovery is considered as a major milestone in the field of immunology and the cloning of its cDNA which allowed the production of recombinant IL-2 is considered as a turning point in immunology research. IL-2 is also one of the oldes
发表于 2025-3-30 23:31:09 | 显示全部楼层
IpilimumabFDA both as an adjuvant therapy for surgically-treated ‘high-risk’ melanoma patients and as primary treatment for unresectable metastatic melanoma patients. It is a monoclonal antibody against CTLA-4, a negative regulatory receptor on T-cells. The current chapter describes potential benefits of CTLA
发表于 2025-3-31 04:12:34 | 显示全部楼层
Nivolumabved by US FDA for the treatment of metastatic melanoma in December 2014 and its combination with ipilimumab was approved in September 2015. Nivolumab is a monoclonal antibody against the PD-1 receptor. PD-1 belongs to the immunoglobulin superfamily of proteins and is expressed on the cell surface of
发表于 2025-3-31 07:00:26 | 显示全部楼层
发表于 2025-3-31 10:06:28 | 显示全部楼层
发表于 2025-3-31 15:40:47 | 显示全部楼层
Promising Immunotherapeutic Approaches in Clinical Trialsged the academic and the industry-based scientists to continue research on immunotherapy of cancer. Apart from monoclonal antibodies, several types of strategies are developed for the treatment of melanoma and other types of cancers. Most of the strategies were found to be well tolerated and showed
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-17 09:06
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表